AT1 FY21 - General Discussion + FA, page-624

I'm estimating revenue around the $3M mark which would be a pass.

Both FDA and Indian approvals are still in the air which are very important for Atomo to secure to take advantage of the multiyear COVID testing opportunity.

The market is waiting. The cashflow and revenue derisk from these deals substantially derisk the business.

We haven't heard news of any further deal developments particularly as John Kelly hinted at further diseases to be onboarded late last year.

An update on manufacturing capacity and inventory levels would also be useful.